[go: up one dir, main page]

ZA951059B - 4-amino-1-piperidylbenzoylguanidine - Google Patents

4-amino-1-piperidylbenzoylguanidine

Info

Publication number
ZA951059B
ZA951059B ZA951059A ZA951059A ZA951059B ZA 951059 B ZA951059 B ZA 951059B ZA 951059 A ZA951059 A ZA 951059A ZA 951059 A ZA951059 A ZA 951059A ZA 951059 B ZA951059 B ZA 951059B
Authority
ZA
South Africa
Prior art keywords
alk
hal
opt
alkylene
amino
Prior art date
Application number
ZA951059A
Other languages
English (en)
Inventor
Rolf Gericke
Dieter Dorsch
Klaus-Otto Minck
Manfred Baumgarth
Norbert Beier
Ingeborg Lues
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA951059B publication Critical patent/ZA951059B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ZA951059A 1994-02-10 1995-02-09 4-amino-1-piperidylbenzoylguanidine ZA951059B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4404183A DE4404183A1 (de) 1994-02-10 1994-02-10 4-Amino-1-piperidylbenzoylguanidine

Publications (1)

Publication Number Publication Date
ZA951059B true ZA951059B (en) 1995-10-13

Family

ID=6509922

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA951059A ZA951059B (en) 1994-02-10 1995-02-09 4-amino-1-piperidylbenzoylguanidine

Country Status (22)

Country Link
US (1) US5461066A (xx)
EP (1) EP0667341B1 (xx)
JP (1) JPH07267926A (xx)
KR (1) KR950321212A (xx)
CN (1) CN1082948C (xx)
AT (1) ATE204864T1 (xx)
AU (1) AU693496B2 (xx)
CA (1) CA2142070A1 (xx)
CZ (1) CZ286681B6 (xx)
DE (2) DE4404183A1 (xx)
DK (1) DK0667341T3 (xx)
ES (1) ES2161789T3 (xx)
GR (1) GR3036839T3 (xx)
HU (1) HU215601B (xx)
NO (1) NO303685B1 (xx)
PL (1) PL179255B1 (xx)
PT (1) PT667341E (xx)
RU (1) RU2140412C1 (xx)
SK (1) SK281721B6 (xx)
TW (1) TW291476B (xx)
UA (1) UA43834C2 (xx)
ZA (1) ZA951059B (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328352A1 (de) 1993-08-24 1995-03-02 Hoechst Ag Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421495A1 (de) * 1994-06-20 1995-12-21 Merck Patent Gmbh Heterocyclyloxy-benzoylguanidine
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
DE4430861A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19608161A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19608162A1 (de) * 1996-03-04 1997-09-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
US7620611B1 (en) * 1999-07-20 2009-11-17 Trilithic, Inc. Neural networks for ingress monitoring
CA2397981C (en) * 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
CZ20032017A3 (cs) * 2001-01-31 2004-05-12 Pfizeráproductsáinc Ethanoláty inhibitoru sodík@vodík měniče typu �Ź způsob jejich přípravyŹ jejich použití a farmaceutický prostředekŹ který je obsahuje
ATE466014T1 (de) * 2001-12-28 2010-05-15 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (es) * 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
SI1556045T1 (sl) * 2002-10-04 2007-02-28 Ucb Sa Derivati 4-aminopiperidina, postopek izdelave in uporaba v medicini
US7601740B2 (en) * 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
CN101014595A (zh) * 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
DK1794126T3 (da) * 2004-09-27 2013-06-24 Acadia Pharm Inc Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
SI2200610T1 (en) * 2007-09-21 2018-06-29 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
ES2890492T3 (es) 2015-07-20 2022-01-20 Acadia Pharm Inc Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE4117904A1 (de) * 1991-05-31 1992-12-03 Basf Ag Substituierte n-phenylpiperidine
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP0589336B1 (de) * 1992-09-22 1997-01-08 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
EP0600371B1 (de) * 1992-12-02 1999-02-03 Hoechst Aktiengesellschaft Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
PT667341E (pt) 2001-12-28
RU95101843A (ru) 1997-03-10
JPH07267926A (ja) 1995-10-17
CA2142070A1 (en) 1995-08-11
TW291476B (xx) 1996-11-21
SK281721B6 (sk) 2001-07-10
NO303685B1 (no) 1998-08-17
RU2140412C1 (ru) 1999-10-27
HUT72306A (en) 1996-04-29
HU9500396D0 (en) 1995-03-28
GR3036839T3 (en) 2002-01-31
EP0667341B1 (de) 2001-08-29
NO950485D0 (no) 1995-02-09
AU693496B2 (en) 1998-07-02
ES2161789T3 (es) 2001-12-16
DE59509543D1 (de) 2001-10-04
DK0667341T3 (da) 2001-10-22
UA43834C2 (uk) 2002-01-15
PL179255B1 (pl) 2000-08-31
ATE204864T1 (de) 2001-09-15
PL307190A1 (en) 1995-08-21
DE4404183A1 (de) 1995-08-17
CN1112550A (zh) 1995-11-29
NO950485L (no) 1995-08-11
EP0667341A1 (de) 1995-08-16
HU215601B (hu) 1999-01-28
US5461066A (en) 1995-10-24
KR950321212A (ko) 1995-12-20
SK15795A3 (en) 1995-09-13
CN1082948C (zh) 2002-04-17
CZ286681B6 (en) 2000-06-14
CZ32795A3 (en) 1995-10-18
AU1157195A (en) 1995-08-17

Similar Documents

Publication Publication Date Title
TW291476B (xx)
DE59610164D1 (de) Arylalkyl-diazinone als Phosphodiesterase IV-Hemmer
PT93687A (pt) Processo para a preparacao de antagonistas de serotonina de tetra-hidrobenz,d}indole
DE69232681D1 (de) 4-oxozyklische harnstoffe mit antiarrhythmische und entfibrillatorische wirkung
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
DE3876402D1 (de) N-(2-alkyl-3-mercapto-1,5-dioxoalkyl)glycinamid-derivate und deren verwendung als kollagenase-inhibitoren.
ATE226202T1 (de) Zyklische harnstoffe mit antiarrhythmischer und antifibrillatorischer wirkung
ATE64734T1 (de) Pyran-derivate.
ES8602797A1 (es) Procedimiento para preparar 11-piperazinil-5h-imidazo(2, 1-c) (1, 4) benzodiazepinas
ES2008633A6 (es) Un procedimiento para la obtencion de derivados de tiofeno.